Contact
Ross McNaughton

Ross McNaughton

Partner

Read More
Contact
Ross McNaughton

Ross McNaughton

Partner

Read More

23 January 2023

Ross McNaughton recognised in The Lawyer's 2023 Hot 100

Specialist technology and life sciences partner Ross McNaughton has been recognised in The Lawyer's Hot 100 2023 list.

Celebrating talent from across the legal industry The Hot 100 brings together exceptional individuals renowned for their expertise, and who achieve stand out success for their clients.

A lead partner within the firm's Tier 1-ranked venture capital and biotechnology practices in Cambridge, Ross was recognised for his expertise in Deep Tech, 'advising companies working on the most interesting technology of tomorrow, helping them through all stages of their life cycle'. The Lawyer highlights that 'it will be McNaughton who will have been behind the scenes' encountering the innovations helping to combat climate change or helping to fight cancer better.

Ross' experience and time spent with clients in international markets was also noted alongside his work in Cambridge 'tapping into the city's rich innovation ecosystem.' 

Commenting on this latest recognition, Ross said: "Our clients are making a real difference to society and the world we live in. Working with them and being able to see the next wave of innovation coming over the horizon is truly inspirational. It's really rewarding to play a part in the important changes they affect, and I'm delighted to be included in The Hot 100 list this year which recognises the significance that life sciences and deep tech have for our future."

Managing Partner Shane Gleghorn commented: "Ross has a passion and a deep understanding of the technology and life sciences sectors that makes him an extraordinary lawyer. He has immersed himself in our clients’ businesses, contributing to their success, and this is reflected in his reputation and this well-deserved accolade."

View The Lawyer Hot 100 2023 in full.

Call To Action Arrow Image

Latest insights in your inbox

Subscribe to newsletters on topics relevant to you.

Subscribe
Subscribe

Related Insights

Suspension bridge
Corporate/M&A & capital markets

Advising Panmure Gordon on £6 million placing for biopharmaceutical group Arecor Therapeutics

7 September 2022

by Ross McNaughton and Tom Benjamin

Click here to find out more
Explaining strategy
Corporate/M&A & capital markets

Nuclera raises additional capital for eProtein™ desktop bioprinter to close Series B funding at $58 million

14 July 2022

by multiple authors

Click here to find out more
White microscope on yellow background
Corporate/M&A & capital markets

Advising New Science Ventures as lead investor on Paragraf's $60 million Series B funding round

4 March 2022

by Ross McNaughton and Adrian Toutoungi

Click here to find out more